The DOI matches its Crossref record; 278 of the 284 references it cites were found in a registry or an index.
Insulin-Like Growth Factor 1 (IGF-1) Signaling in Glucose Metabolism in Colorectal Cancer
Open accessAbstract
Colorectal cancer (CRC) is one of the most common aggressive carcinoma types worldwide, characterized by unfavorable curative effect and poor prognosis. Epidemiological data re-vealed that CRC risk is increased in patients with metabolic syndrome (MetS) and its serum components (e.g., hyperglycemia). High glycemic index diets, which chronically raise post-prandial blood glucose, may at least in part increase colon cancer risk via the insulin/insulin-like growth factor 1 (IGF-1) signaling pathway. However, the underlying mechanisms linking IGF-1 and MetS are still poorly understood. Hyperactivated glucose uptake and aerobic glycolysis (the Warburg effect) are considered as a one of six hallmarks of cancer, including CRC. However, the role of insulin/IGF-1 signaling during the acquisition of the Warburg metabolic phenotypes by CRC cells is still poorly understood. It most likely results from the interaction of multiple processes, directly or indirectly regulated by IGF-1, such as activation of PI3K/Akt/mTORC, and Raf/MAPK signaling pathways, activation of glucose transporters (e.g., GLUT1), activation of key glycolytic enzymes (e.g., LDHA, LDH5, HK II, and PFKFB3), aberrant expression of the oncogenes (e.g., MYC, and KRAS) and/or overexpression of signaling proteins (e.g., HIF-1, TGF-β1, PI3K, ERK, Akt, and mTOR). This review describes the role of IGF-1 in glucose metabolism in physiology and colorectal carcinogenesis, including the role of the insulin/IGF system in the Warburg effect. Furthermore, current therapeutic strategies aimed at repairing impaired glucose metabolism in CRC are indicated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Schematic illustration of the insulin/IGF-1 system involved in the development and progression of colorectal cancer (CRC) through direct (mitotic effects) and indirect (aerobic glycolysis) activity. [↑,↓-increase (up-regulation)/decrease (down-regulation) expression/level; AMPK-adenosine monophosphate (AMP)-activated protein kinase; CRNDE-colorectal neoplasia differentially expressed gene; GLUT-glucose transporter; GH-R-growth hormone receptor; GRP78-glucose-regulated protein 78; HIF-1α, -β-hypoxia-inducible transcription factor-1α, -β; HK II-hexokinase II; IGF-1-insulin-like growth factor 1; IGFBP-1;-2-IGF binding proteins 1,-2; JAK/STAT3-Janus kinase/signal transducer and activator of transcription; KLK10-kallikrein-related peptidase; LDHA, -5-lactate dehydrogenase A, -5; mKRAS-mutant KRAS gene; mMYC-mutant MYC gene; mTP53-mutant tumor protein 53 gene; PI3K/Akt/mTOR-phosphatidylinositol 3 kinase/Akt/mammalian target of rapamycin complex; WAT-white adipose tissue].](/paper-figures/f88b765def11457a838eb19e9a83d462/insulin-like-growth-factor-1-igf-1-signaling-in-glucose-metabolism-in-colorectal-figure-1.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“IGF1 and IGF2 have substantial effects on cell proliferation and differentiation and are effective inhibitors of apoptosis [174].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [174]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Zaafar, D. K., Zaitone, S. A., & Moustafa, Y. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100562 · Cited by 76
RetractedWu, X., Wang, L., Yang, D., Qu, M., Yang, Y., Guo, F. Y., Han, L., & Xue, J. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26399 · Cited by 51
RetractedSung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425
The consensus molecular subtypes of colorectal cancer
Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3967 · Cited by 5,170
The Warburg Effect: How Does it Benefit Cancer Cells?
Liberti, M. V., & Locasale, J. W. (2016) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2015.12.001 · Cited by 5,150
mTOR: from growth signal integration to cancer, diabetes and ageing
Zoncu, R., Efeyan, A., & Sabatini, D. M. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3025 · Cited by 3,941
Insulin and insulin-like growth factor signalling in neoplasia
Pollak, M. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2536 · Cited by 2,059
DAUGHADAY, W. H., & ROTWEIN, P. (1989) · Endocrine Reviews · doi:10.1210/edrv-10-1-68 · Cited by 1,725
Cited by
Drug Resistance in Colorectal Cancer: From Mechanism to Clinic
Wang, Q., Shen, X., Chen, G., & Du, J. (2022) · Cancers · doi:10.3390/cancers14122928 · Cited by 160
Metabolic reprogramming consequences of sepsis: adaptations and contradictions
Liu, J., Zhou, G., Wang, X., & Liu, D. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04490-0 · Cited by 164
Dai, F., Zhang, J., Chen, F., Chen, X., Lee, C. J., Liang, H., Zhao, L., & Tan, H. F. (2024) · Advanced Science · doi:10.1002/advs.202408783 · Cited by 135
Targeting of the tumor immune microenvironment by metformin
Wu, Z., Zhang, C., & Najafi, M. (2021) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-021-00648-w · Cited by 83
Screening for Coronary Artery Disease in Cancer Survivors
Velusamy, R., Nolan, M. T., Murphy, A. J., Thavendiranathan, P., & Marwick, T. H. (2023) · JACC CardioOncology · doi:10.1016/j.jaccao.2022.12.007 · Cited by 76
Metadata
- Authors
- Kasprzak, A.
- Affiliations
- Poznan University of Medical Sciences (PL)
- Corresponding author
- Kasprzak, Aldona
- ORCID
- Kasprzak, Aldona
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-06-16
- Volume
- 22
- Issue
- 12
- Pages
- 6434
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC8234711
- OpenAlex
- W3169775278
- Cited by
- 248
- References
- 284
- Citations by year
- 2026: 51 · 2025: 73 · 2024: 60 · 2023: 32 · 2022: 22 · 2021: 10
- FWCI
- 5.03
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- insulin-like growth factor I, colorectal cancer, glucose metabolism, Warburg effect, aerobic glycolysis, metabolic syndrome, hyperglycemia, PI3K/AKT/mTOR pathway, glucose transporters, GLUT1, glycolytic enzymes, c-Myc, KRAS, HIF-1, TGF-β1, colorectal carcinogenesis
- MeSH terms
- Animals, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Disease Susceptibility, Glucose, Humans, Insulin-Like Growth Factor I, Metabolic Diseases, Risk Factors, Colorectal Neoplasms, Signal Transduction, Biomarkers, Gene Expression Regulation, Neoplastic, Carbohydrate Metabolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Insulin-Like Growth Factor 1 (IGF-1) Signaling in Glucose Metabolism in Colorectal Cancer. https://app.cochat.ai/papers/10.3390/ijms22126434
- The paper
- Kasprzak, A. (2021). Insulin-Like Growth Factor 1 (IGF-1) Signaling in Glucose Metabolism in Colorectal Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms22126434
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.